203 related articles for article (PubMed ID: 30273976)
21. Provider-directed marketing may increase prescribing of medications for opioid use disorder.
Nguyen T; Andraka-Christou B; Simon K; Bradford WD
J Subst Abuse Treat; 2019 Sep; 104():104-115. PubMed ID: 31370974
[TBL] [Abstract][Full Text] [Related]
22. Effects of Physician-directed Pharmaceutical Promotion on Prescription Behaviors: Longitudinal Evidence.
Datta A; Dave D
Health Econ; 2017 Apr; 26(4):450-468. PubMed ID: 26893065
[TBL] [Abstract][Full Text] [Related]
23. Association of Pharmaceutical Manufacturer Payments to Physicians and Prescribing Dosage of Opioids.
Fleischman W; Agrawal S; Gross CP; Ross JS
J Gen Intern Med; 2019 Jul; 34(7):1074-1076. PubMed ID: 31011967
[No Abstract] [Full Text] [Related]
24. Disclosure of industry payments to prescribers: industry payments might be a factor impacting generic drug prescribing.
Qian J; Hansen RA; Surry D; Howard J; Kiptanui Z; Harris I
Pharmacoepidemiol Drug Saf; 2017 Jul; 26(7):819-826. PubMed ID: 28485111
[TBL] [Abstract][Full Text] [Related]
25. Prescribing Patterns and Costs Associated with Postoperative Eye Drop Use in Medicare Beneficiaries Undergoing Cataract Surgery.
Zafar S; Wang P; Schein OD; Srikumaran D; Makary M; Woreta FA
Ophthalmology; 2020 May; 127(5):573-581. PubMed ID: 31952884
[TBL] [Abstract][Full Text] [Related]
26. Industry Payments to Physician Specialists Who Prescribe Repository Corticotropin.
Hartung DM; Johnston K; Cohen DM; Nguyen T; Deodhar A; Bourdette DN
JAMA Netw Open; 2018 Jun; 1(2):e180482. PubMed ID: 30646086
[TBL] [Abstract][Full Text] [Related]
27. Association of Pharmaceutical Industry Marketing of Opioid Products With Mortality From Opioid-Related Overdoses.
Hadland SE; Rivera-Aguirre A; Marshall BDL; Cerdá M
JAMA Netw Open; 2019 Jan; 2(1):e186007. PubMed ID: 30657529
[TBL] [Abstract][Full Text] [Related]
28. Payments from drug companies to physicians are associated with higher volume and more expensive opioid analgesic prescribing.
Zezza MA; Bachhuber MA
PLoS One; 2018; 13(12):e0209383. PubMed ID: 30566426
[TBL] [Abstract][Full Text] [Related]
29. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study.
Fleischman W; Agrawal S; King M; Venkatesh AK; Krumholz HM; McKee D; Brown D; Ross JS
BMJ; 2016 Aug; 354():i4189. PubMed ID: 27540015
[TBL] [Abstract][Full Text] [Related]
30. Sunshine Act: shedding light on inaccurate disclosures at a gynecologic annual meeting.
Thompson JC; Volpe KA; Bridgewater LK; Qeadan F; Dunivan GC; Komesu YM; Cichowski SB; Jeppson PC; Rogers RG
Am J Obstet Gynecol; 2016 Nov; 215(5):661.e1-661.e7. PubMed ID: 27319366
[TBL] [Abstract][Full Text] [Related]
31. Pharmaceutical opioid marketing and physician prescribing behavior.
Beilfuss S; Linde S
Health Econ; 2021 Dec; 30(12):3159-3185. PubMed ID: 34562329
[TBL] [Abstract][Full Text] [Related]
32. Industry-sponsored meal payments are associated with prescriptions and Medicare expenditures on brand-name colchicine in the United States.
Murayama A
Int J Rheum Dis; 2024 Jan; 27(1):e14962. PubMed ID: 37923570
[TBL] [Abstract][Full Text] [Related]
33. The impact of reducing pharmaceutical industry payments on physician prescribing.
Parker-Lue S
Health Econ; 2020 Mar; 29(3):382-390. PubMed ID: 31930636
[TBL] [Abstract][Full Text] [Related]
34. Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies.
Hollenbeck BK; Oerline M; Kaufman SR; Caram MEV; Dusetzina SB; Ryan AM; Shahinian VB
Urology; 2021 Feb; 148():134-140. PubMed ID: 33075381
[TBL] [Abstract][Full Text] [Related]
35. Physicians, pharmaceutical sales representatives, and the cost of prescribing.
Caudill TS; Johnson MS; Rich EC; McKinney WP
Arch Fam Med; 1996 Apr; 5(4):201-6. PubMed ID: 8769907
[TBL] [Abstract][Full Text] [Related]
36. Receipt of Promotional Payments at the Individual and Physician Network Level Associated with Higher Branded Antipsychotic Prescribing Rates.
Hollands S
Adm Policy Ment Health; 2020 Jan; 47(1):73-85. PubMed ID: 31515636
[TBL] [Abstract][Full Text] [Related]
37. Nonresearch Industry Payments to Radiologists: Characteristics and Associations With Regional Medical Imaging Utilization.
Kokabi N; Junn JC; Xing M; Hemingway J; Hughes DR; Duszak R
J Am Coll Radiol; 2017 Mar; 14(3):418-425.e2. PubMed ID: 28082155
[TBL] [Abstract][Full Text] [Related]
38. Medicare Part D payments for neurologist-prescribed drugs.
De Lott LB; Burke JF; Kerber KA; Skolarus LE; Callaghan BC
Neurology; 2016 Apr; 86(16):1491-8. PubMed ID: 27009256
[TBL] [Abstract][Full Text] [Related]
39. Physician-Industry Interactions and Anti-Vascular Endothelial Growth Factor Use Among US Ophthalmologists.
Taylor SC; Huecker JB; Gordon MO; Vollman DE; Apte RS
JAMA Ophthalmol; 2016 Aug; 134(8):897-903. PubMed ID: 27356110
[TBL] [Abstract][Full Text] [Related]
40. Deciphering the Sunshine Act: Transparency Regulation and Financial Conflicts in Health Care.
Saver RS
Am J Law Med; 2017 Nov; 43(4):303-343. PubMed ID: 29452562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
